COVID-19 Resource Center / COVID-19 Outpatient Therapeutics - Health Care Professionals
COVID-19 Outpatient Therapeutics - Health Care Professionals
General Information for Health Care Professionals
Stanford Health Care is offering COVID-19 therapeutics for treatment or prevention in eligible patients, whether within or outside of the Stanford Health Care system, in accordance with national guidelines.
Due to the evolving variants and supply of medications, Stanford Health Care will select the specific therapeutic based individual patient factors.
For questions, please contact us at 650-391-8503.
Stanford Health Care reserves the right to select based on medication supply and clinical data available at the time of referral.
Are you a patient?
General Information for Health Care Professionals
Stanford Health Care is offering COVID-19 therapeutics for treatment or prevention in eligible patients, whether within or outside of the Stanford Health Care system, in accordance with national guidelines.
Due to the evolving variants and supply of medications, Stanford Health Care will select the specific therapeutic based individual patient factors.
Stanford Health Care reserves the right to select based on medication supply and clinical data available at the time of referral.
Are you a patient?
For questions, please contact us at 650-391-8503.
Post-exposure prophylaxis – Jan. 19, 2022
No monoclonals active against the omicron variant are available for post-exposure prophylaxis.
Confirming Patient Eligibility
- Positive direct SARS-CoV-2 viral testing
- Be symptomatic with onset within the previous 7 days
a. Symptoms include at least one of the following: fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath with exertion - Meet one or more high-risk criteria (see below)
High-risk criteria
- BMI >25 kg/m2
- Chronic kidney disease
- Diabetes mellitus
- Immunosuppressive disease/therapy — this does not include:
- HIV alone with CD4 >200 CD4+ T cells/mm3
- Prednisone or prednisone equivalent <20 mg daily for <3 weeks
- Pregnancy
- Age >= 50 years
- Cardiovascular disease including congenital heart disease, hypertension
- Chronic respiratory disease including chronic obstructive pulmonary disease
- Sickle cell disease
- Neurodevelopmental disorders
For the most current information on conditions that may increase risk for severe COVID, please refer to the CDC guidance
Referral Process Overview
Step 1: Familiarize Yourself
- Stanford Health Care reserves the right to select the medication therapy based on medication supply and clinical data available at the time of referral.
Step 2: Educate the Patient
- Inform the patient of the current therapies that are unapproved therapies but are authorized by the FDA for use under Emergency Use Authorization. Click here for information that may assist in explaining EUA to patients.
- Discuss the risks, benefits, and alternatives to therapies with patients.
- If the patient is interested in pursuing therapy:
- The referral will be screened to ensure that the patient is eligible for therapy.
- If approved, the patient will be contacted via phone to schedule an appointment and will receive detailed information about what to expect.
- If denied, the patient will be informed of the reason for denial.
Step 4: Follow-up & Reporting
- If the patient experienced an adverse reaction, the provider must report it to all of the following:
- FDA MedWatch
- Manufacturer
- Enter a SAFE Event (Stanford Health Care-privileged providers only) or email DL-SHC-Pharmacy-COVID@stanfordhealthcare.org.